PTGS2 and cancer: Interestingly, preclinical and clinical trials using different Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), blocking COX-2 and subsequent prostaglandin production, have reported a decrease in cancer incidence, tumor cell dissemination, and finally global cancer morbidity.